{"id":"294359117093-66","name":"UCB","registrationDate":"2015-04-24T10:35:14.049+02:00","category":2,"subCategory":3,"legal":"Public Limited Company","web":"http://www.ucb.com","country":"Belgium","headAddress":"Allée de la Recherche 60","headCity":"Brussels","headPostCode":"1070","headPhone":"(32)25 59 99 99","boss":"Jean-Christophe Tellier","bossTitle":"Mr","bossPosition":"CEO","membersCount":2,"membersFTE":"0.75","membership":"EFPIA = European Federation of Pharmaceutical Industries and Associations&#xd;\n(http://efpia.eu/)&#xd;\n&#xd;\nEBE = European Biopharmaceuticals Entreprises (http://www.ebe-biopharma.eu/)","memberOrga":"","goal":"UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. With approximately 7,500 people operating in 40 countries, the company generated revenue of € 4.5 billion in 2017. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news","acronym":"","interests":"Competition, Consumer Affairs, Economic and Financial Affairs, Employment and Social Affairs, Information Society, Internal Market, Public Health, Research and Technology","euInitiatives":"Engage governments and policymakers worldwide on issues important to UCB to:&#xd;<br />• Ensure patients have access to medicines they need&#xd;<br />• Provide coverage and reimbursement that reward innovation&#xd;<br />• Introduce sound, science-based regulation&#xd;<br />• Enable biotechnology research and development (R&amp;D)","lastUp":"2018-04-04T10:04:20.820+02:00","customers":"","costAbsolu":"","costRange":"200000-299999","turnoverAbsolu":0,"turnoverRange":""}